Newstral
Article
The New York Times on 2019-08-08 01:39
Novartis C.E.O. Defends Company’s Decision to Withhold False Data From the F.D.A.
Related news
Novartis CEO defends call to withhold data from FDAnwaonline.com
Novartis Sues Janssen Over Tremfya® False Advertisingjdsupra.com
F.D.A. Approves New Drug for FluThe New York Times
F.D.A. Moves to Stop Use of Unapproved Stem Cell TherapiesThe New York Times
F.D.A. says Canadian Company, CanaRx, Sells Unsafe Medicines to U.S. BuyersThe New York Times
Women Should Be Warned of Breast Implant Hazards, F.D.A. SaysThe New York Times
In ‘Power Grab,’ Health Secretary Azar Asserts Authority Over F.D.A.The New York Times
F.D.A. Authorizes Third Vaccine Dose for ImmunocompromisedThe New York Times
F.D.A. Says It Will Resume Inspections of Some High-Risk FoodsThe New York Times
Drug to Treat Smallpox Approved by F.D.A., a Move Against BioterrorismThe New York Times
Mammogram Centers Must Tell Women if They Have Dense Breasts, F.D.A. ProposesThe New York Times
Juul Shake-up: C.E.O. Steps DownThe New York Times
Only Romaine From Central and Northern California Is Unsafe, F.D.A. SaysThe New York Times
Government Shutdown Curtails F.D.A. Food InspectionsThe New York Times
Who’s Missing From Breast Cancer Trials? Men, Says the F.D.A.The New York Times
New Sex Drug for Women to Improve Low Libido Is Approved by the F.D.A.The New York Times
Senate Confirms Stephen Hahn to Head F.D.A.The New York Times
Novartis Settles False Claims Act Cases and Pays $729 Million for Domestic Bribery Schemesjdsupra.com
With Minimal Evidence, Trump Asks F.D.A. to Study Malaria Drugs for CoronavirusThe New York Times